Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation antiepileptic drugs (AEDs) currently available and must make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic market that developers of new AED brands will enter. Our Treatment Algorithms offering provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Geographies: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Vimpat, Aptiom, Briviact, Fycompa, Lyrica, levetiracetam, lamotrigine, cabamazepine and oxcarbazepine, valproates, others.
Key analysis provided: